{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:37:32Z","timestamp":1781545052806,"version":"3.54.5"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.smim.2020.101437","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:03:14Z","timestamp":1606608194000},"page":"101437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Adoptive T cell therapy: Boosting the immune system to fight cancer"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-7709","authenticated-orcid":false,"given":"Ernesto","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuveer","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2020.101437_bib0005","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101437_bib0010","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.161.10.5133","article-title":"Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model","volume":"161","author":"Romieu","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1173","article-title":"How T cells \u201csee\u201d antigen","volume":"6","author":"Krogsgaard","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101437_bib0025","first-page":"651","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive t cells","volume":"546","author":"Jha","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0030","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","article-title":"Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection","volume":"91","author":"Sakaguchit","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2020.101437_bib0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.smim.2020.101437_bib0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101437_bib0045","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0050","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0055","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CJI.0000000000000223","article-title":"Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases","volume":"41","author":"Mehta","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0065","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0070","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0075","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus\u2013associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0080","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","article-title":"Generating CTLS against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies","volume":"101","author":"Gottschalk","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0085","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CJI.0b013e318279652e","article-title":"Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies","volume":"36","author":"Ramos","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.uct.2008.01.001","article-title":"Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens","volume":"3","author":"Craddock","year":"2008","journal-title":"Update Cancer Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0100","first-page":"3630","article-title":"Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design","volume":"62","author":"Zeng","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.138.3.989","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma","volume":"138","author":"Muul","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0110","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of TUMOR-INFILTRATING lymphocytes and INTERLEUKIN-2 in the immunotherapy of patients with METASTATIC MELANOMA","volume":"281","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The tumor microenvironment represses t cell mitochondrial biogenesis to drive intratumoral t cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101437_bib0120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-017-0219-7","article-title":"Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2\/neu tumor antigen epitopes","volume":"18","author":"Kuznetsova","year":"2017","journal-title":"BMC Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2020.101437_bib0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101437_bib0140","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.174.7.4415","article-title":"Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines","volume":"174","author":"Zhao","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0145","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.4049\/jimmunol.171.6.3287","article-title":"High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens","volume":"171","author":"Morgan","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0155","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","article-title":"Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6","volume":"21","author":"Lindsey","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.smim.2020.101437_bib0165","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","article-title":"Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific t cell functions","volume":"180","author":"Robbins","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0170","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.4049\/jimmunol.1000173","article-title":"Evidence for a TCR affinity threshold delimiting maximal CD8 t cell function","volume":"184","author":"Schmid","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aac5624","article-title":"High-throughput pairing of T cell receptor \u03b1 and \u03b2 sequences","volume":"7","author":"Howie","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00268","article-title":"Structure-based, rational design of T cell receptors","volume":"4","author":"Zoete","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0185","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ymthe.2018.12.010","article-title":"Improving t cell receptor on-target specificity via structure-guided design","volume":"27","author":"Hellman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0190","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.4049\/jimmunol.1302344","article-title":"Specific increase in potency via structure-based design of a TCR","volume":"193","author":"Malecek","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003478","article-title":"Computational design of the affinity and specificity of a therapeutic t cell receptor","volume":"10","author":"Pierce","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.smim.2020.101437_bib0200","first-page":"595","article-title":"A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces","volume":"29","author":"Riley","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.smim.2020.101437_bib0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2001.6148","article-title":"NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma","volume":"98","author":"Goydos","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.smim.2020.101437_bib0215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0220","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0225","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0230","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0235","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.smim.2020.101437_bib0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Seliger","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.smim.2020.101437_bib0245","doi-asserted-by":"crossref","first-page":"E10702","DOI":"10.1073\/pnas.1810653115","article-title":"Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules","volume":"115","author":"Bethune","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101437_bib0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0255","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0260","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1\u2013Presented peptide as a cross-reactive target for engineered MAGE A3\u2013Directed t cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/2326-6066.CIR-19-0134","article-title":"A high-avidity T-cell receptor redirects natural killer T-cell specificity and outcompetes the endogenous invariant T-cell receptor","volume":"8","author":"Landoni","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101437_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1717-8","article-title":"T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.smim.2020.101437_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02503","article-title":"Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific t cell receptors with minimal TCR mispairing","volume":"9","author":"Campillo-Davo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0280","series-title":"Cancer Immunotherapy With T Cells Carrying Bispecific Receptors That Mimic Antibodies","author":"Ahn","year":"2019"},{"key":"10.1016\/j.smim.2020.101437_bib0285","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-based design of chimeric antigen receptor for t cell engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0290","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors","volume":"25","author":"Balakrishnan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0295","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101437_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101437_bib0310","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0315","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0320","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the \u03b3 or \u03b6 subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101437_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/stke.3202006re1","article-title":"Inhibition of immune responses by ITAM-bearing receptors","volume":"2006","author":"Hamerman","year":"2006","journal-title":"Sci. STKE"},{"key":"10.1016\/j.smim.2020.101437_bib0330","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101437_bib0340","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0345","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2020.101437_bib0350","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101437_bib0355","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","article-title":"THEMIS-SHP1 recruitment by 4-1BB tunes LCK-Mediated priming of chimeric antigen receptor-redirected t cells","volume":"37","author":"Sun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2020.101437_bib0360","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase\/AKT\/Bcl-X L activation and CD8 T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0365","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing EphA2-CAR t cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.smim.2020.101437_bib0370","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-Specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0375","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101437_bib0380","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-Cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0385","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101437_bib0390","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase i trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0395","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101437_bib0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0410","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0415","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0420","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated k light chains find the latest version : clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101437_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR t cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0430","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.smim.2020.101437_bib0435","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0440","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0445","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0450","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0460","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2020.101437_bib0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101437_bib0470","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0475","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101437_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2020.101437_bib0485","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101437_bib0490","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0495","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 selectively modulates the toxicities of CD19-Specific chimeric antigen receptor-modified t cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0500","first-page":"5400","article-title":"ERBB-2 (HER2\/neu) gene copy number, p185HER2 overexpression, and intratumor heterogeneity in human breast Cancer","volume":"55","author":"Feuerstein","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0505","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of t cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0510","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.smim.2020.101437_bib0515","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational Targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0520","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013Driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.smim.2020.101437_bib0525","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0530","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0535","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","article-title":"Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses","volume":"16","author":"Peng","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0540","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified t cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0545","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0550","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0555","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101437_bib0560","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0565","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101437_bib0570","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.smim.2020.101437_bib0575","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0580","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0585","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.smim.2020.101437_bib0590","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0595","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate t cell receptor \u03b6-Chain and induce a regulatory phenotype in naive t cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0600","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0605","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101437_bib0610","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2020.101437_bib0615","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"Serafini","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.smim.2020.101437_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00032","article-title":"Starved and asphyxiated: How can CD8+ T cells within a tumor microenvironment prevent tumor progression","volume":"7","author":"Zhang","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0625","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni.2386","article-title":"Metabolic checkpoints in activated T cells","volume":"13","author":"Wang","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0630","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101437_bib0635","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Garcia-Manero","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0640","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00262-008-0494-5","article-title":"Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression","volume":"57","author":"Su","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0645","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101437_bib0650","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2005.09.009","article-title":"Alterations in components of the TGF-\u03b2 superfamily signaling pathways in human cancer","volume":"17","author":"Levy","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2020.101437_bib0655","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.4049\/jimmunol.174.5.3015","article-title":"Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-Activated macrophages: implications for burkitt\u2019s lymphoma","volume":"174","author":"Ogden","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0660","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-017-2043-6","article-title":"IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model","volume":"66","author":"ei Ito","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0665","first-page":"1","article-title":"The relevance of the TGF-\u03b2 Paradox to EMT-MET program","volume":"23","author":"Chevaun","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.smim.2020.101437_bib0670","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-011-1855-x","article-title":"Role of interleukin-10 in breast cancer","volume":"133","author":"Hamidullah","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.smim.2020.101437_bib0675","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0680","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.cji.0000192104.24583.ca","article-title":"Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-\u03b2 receptor","volume":"29","author":"Lacuesta","year":"2006","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101437_bib0685","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101437_bib0690","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0695","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: New insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2020.101437_bib0700","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0705","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.smim.2020.101437_bib0710","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0715","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101437_bib0720","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101437_bib0725","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR t cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101437_bib0730","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFV by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101437_bib0735","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:18:30Z","timestamp":1760915910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":147,"alternative-id":["S1044532320300531"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101437","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive T cell therapy: Boosting the immune system to fight cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101437"}}